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ABSTRACT 
 
Background: 
Lymphedema is a chronic debilitating condition and the curative treatment is yet to be found. 
Tissue engineering approach which combines cellular components, scaffold and molecular 
signals hold great potential in the treatment of secondary lymphedema with the advent of 
lymphatic graft to reconstruct damaged collecting lymphatic vessel. This review highlights 
the ideal characteristics of lymphatic graft, the limitation and challenges faced as well as the 
approaches in developing tissue engineered lymphatic graft. 
 
Methods: 
Literatures on tissue engineering of lymphatic system and lymphatic tissue biology were 
reviewed. 
 
Results: 
The prime challenge in the design and manufacturing of this graft is producing 
endothelialized conduit with intraluminal valves. Suitable scaffold material is needed to 
ensure stability and functionality of the construct. Endothelialization of the construct can be 
enhanced via biofunctionalization and nanotopography which mimics extracellular matrix. 
Nanocomposite polymers with improved performance over existing biomaterials are likely to 
benefit the development of lymphatic graft. 
 
Conclusions: 
In depth understanding of tissue engineering, nanotechnology and improved knowledge on 
the biology of lymphatic regeneration, the aspiration to develop successful lymphatic graft is 
well achievable. 
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1. INTRODUCTION 
 
Lymphedema is a debilitating condition resulting from dysfunction of lymphatic system 
characterised by progressive soft tissue swelling which commonly involves the limbs and 
genitalia. Lymphedema is categorised into primary and secondary lymphedema. Primary 
lymphedema is rare and caused by genetic defects. Secondary lymphedema is common and 
caused by acquired damage secondary to surgical resection (lymph node clearance), tumour 
infiltration, parasitic infection and radiation induced fibrosis.  
In the United Kingdom alone, there are estimated 240,000 people living with lymphedema 
(1). Despite the wide practise of breast conserving surgery and minimal lymphatic 
intervention, the world wide incidence of secondary lymphedema remains high with an 
estimate of 295,320 patients developing upper limb lymphedema yearly after breast cancer 
surgery (2). This huge number highlights the critical clinical need to treat surgery induced 
secondary lymphedema.  
The current armamentarium of therapeutic intervention involves non-surgical and surgical 
treatment. Non-surgical treatment includes bandaging and physiotherapy which does not 
prevent progression of disease and results in poor quality of life. The surgical treatment of 
lymphedema has evolved tremendously over the years. In 1990, Baumeister reported the use 
of lymphatic (lymphatico-lymphatic) bypass graft to bridge damaged lymphatic vessels 
utilising autologous lymphatic graft harvested from ventromedial part of the thigh (3). 
Although reporting a volume reduction of 80% compared to pre-operative conditions, this 
technique did not gain popularity due to the high risk of donor site morbidity. Following the 
same principle, Campisi used vein graft (lymphatic-venous-lymphatic shunt) and reported 
volume reduction of 75% in almost half of his patients(4). Several other form of surgical 
treatment such as liposuction (suction assisted lipectomy), subcutaneous excision and 
ablative surgery with skin grafting were practiced but with poor outcomes. In the recent 
years, surgical treatment of lymphedema has evolved into super-microsurgical approach. The 
techniques undertaken are lymphatic bypass surgery (lymphaticovenular anastomosis) and 
vascularised lymph node transfer. Most authors reported a modest improvement in limb 
volumes (decrease of 30%–50%) although some patients experienced more significant 
improvement (5). However, none of these techniques are curative and they are exclusively for 
patients in early stages of lymphedema. 
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With these challenges in mind, tissue engineered lymphatic graft is an ideal alternative that 
should be explored for the treatment of secondary lymphedema as it is likely to offer greater 
versatility and therapeutic power. The engineered lymphatic graft can be used to bridge 
defects involving collecting lymphatic vessels due to surgical resection or as a bypass for 
congenital cause of blockade to lymphatic circulation. Furthermore, it could also benefit 
patients with venous impairment in the same lymphedema limb that are not suitable candidate 
for lymphovenous shunt. To match the properties of native lymphatic vessel, an ideal 
lymphatic graft should be durable, able to maintain patency, easy to sterilize, non-toxic, non-
allergenic and non-carcinogenic. In terms of handling, it should be kink-resistant, easy to 
suture and have adequate fatigue strength. The goal of tissue engineered lymphatic graft is to 
reproduce the structure, function and cellular organisation of a native collecting lymphatic 
vessel. 
This article aims to discuss the tissue engineering approaches in developing lymphatic graft 
and the unique limitations and challenges involved. This review also features the 
advancement in the knowledge of lymphatic biology, with emphasis on lymphatic 
regeneration and the molecular signals involved. 
 
2.0 TISSUE ENGINEERING OF LYMPHATIC GRAFT 
 
The lymphatic system can be partitioned into five sections: lymphatic capillary, collecting 
lymphatic, lymph nodes, lymphatic trunk and lymphatic duct (Figure 1). The collecting 
lymphatic vessels contain intraluminal (secondary) valves and endothelial cells that are 
spindle shaped with continuous basement membrane, pericytes and associated smooth muscle 
cell (SMC) cover enabling intrinsic contractility of the vessels (6). Collecting lymphatic 
vessels are made up of functional subunits known as lymphangion which propels lymph in a 
peristalsis manner. Lymph flow is driven by local forces and affected by neighbouring 
musculoskeletal movement and vasomotion. The collecting lymphatics have similar wall as 
of blood vessels and its smooth muscle tissue contains specialised pacemaker cells that 
regulate spontaneous electrical activity (Table 1) (7).  
Lymphatic system regulates extracellular fluid homeostasis by preserving tissue fluid 
balance, involved in immune response and absorption of dietary fat. The amount of lymph 
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formation and flow rate is dependent on the characteristics of extracellular matrix (ECM), 
type of tissue and the degree of swelling (8). 
The lymphatic network is lined by specialised endothelial cells known as lymphatic 
endothelial cells (LECs). The LECs embryologically originates from out pouching of blood 
endothelial cells (BECs) from cardinal vein and they both share close structural similarities. 
About 300 genes are expressed differentially between BECs and LECs which includes LEC-
specific genes (LYVE-1, VEGFR-3, prox1, podoplanin, and β-chemokine receptor D6), 
integrins, cadherins, pro-inflammatory cytokines and chemokines (9).  
Three key aspects that tissue engineering could benefit lymphatic system are development of 
artificial lymphatic graft (Figure 2), regeneration of lymphatic network via 
lymphangiogenesis and engineering artificial lymph node. 
Developing tissue engineered lymphatic graft involves proper material selection and 
fabrication of scaffold to create an environment conducive for LEC growth as well as for 
lymphatic regeneration. Although artificial lymphatic graft has yet to be successful, it holds 
great potential as there is possibility of translating technology and knowledge from tissue 
engineered vascular graft.  Regenerating lymphatic network is a long-standing challenge for 
tissue engineers as it required self-organisation of endothelial cells into a network of conduits 
in-vivo. A possible solution is with the use of stem cell technology and growth factors to 
form an extensive network of lymphatic capillary which drains into existing or neighbouring 
collecting lymphatic. Artificial lymph node that is immunologically functional was 
successfully engineered by Watanabe et al (10). Although this artificial organ does not 
enhance lymphatic circulatory function, nevertheless this is a step forward in achieving 
alternative treatment for lymphedema in future.  
The challenges involved in developing lymphatic graft differ from vascular graft. The major 
differences are the mechanical property and hydrostatic pressure. Lymphatic system is a low 
pressure and pulseless system as compared to vascular system. This allows lymphatic graft to 
be built with lower strength and elasticity however intraluminal valve is an essential feature 
to be included to ensure its functionality. The following section discusses on the strategies 
involved in developing lymphatic graft. 
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3.0 STRATEGIES IN DEVELOPMENT OF LYMPHATIC GRAFT 
 
3.1 Lymphatic pressure 
Two primary mechanical forces that require special attention in tissue engineering of 
lymphatic graft are the  transaxial pressure gradient, which governs fluid shear stress; and 
average transmural pressure, which governs circumferential stress(16). These two intrinsic 
pressures work in tandem with extrinsic pressures such as internal tissue pressure, tissue 
osmotic pressure and venous pressure which determine the flow rate of lymphatic fluid (17). 
Intrinsic contraction of lymphatic vessel ranges between 12 and 70mmHg in healthy human. 
The extrinsic pressure in healthy human ranges between 0 and 60mmHg (18). In pathological 
condition, the intrinsic lymphatic pressure is elevated and the accumulation of fibrotic tissue 
as well as adipocytes due to lymph stasis drastically alters the surrounding mechanical 
environment (19, 20). This condition may eventually overwhelm the lymphatic vessels and 
result in decreased contractile tone and frequency of collecting lymphatics as seen in rat 
thoracic duct model (negative chronotrophic and inotrophic effect) (21). However, this is not 
seen in the mesenteric lymphatic vessels which indicated that the amount of reduction varies 
in different location. The pressure gradient at which flow cessation takes place in human is 
yet to be known. It is crucial to quantify these values in diseased human lymphatic system as 
the ability to simulate these pressure ex-vivo is paramount in determining the success of the 
lymphatic graft.  
The advancement of imaging modalities coupled with computational power and image 
processing algorithms has enabled reliable quantification and correlation between lymph flow 
rate and intrinsic contractile activity (11, 12). The use of non-invasive imaging modalities, 
the near-infrared (NIR) fluorescence imaging in combination with the clinically approved 
Indocyanine Green (ICG) dye has enabled researchers to better understand the draining 
velocity of initial lymphatics and contractile physiology of collecting lymphatics in human as 
most previous studies were mostly limited to animal models(13-15).  This advancement in 
imaging has been particularly useful in understanding the changes that takes place in diseased 
lymphatic system which is a step closer to unravelling ways to manipulate the biological and 
mechanical changes taking place in lymphedema.  
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3.2 Mechanical property of Lymphatic Vessel  
The elastic modulus, tensile stress and strain at failure and the burst strength of human 
collecting lymphatic vessel are not as well studied and documented as for arteries and veins 
(22). Several studies have been conducted on animal models however these values might not 
precisely reflect that of human due to difference in size and capacity of the vessel (23-25). An 
ideal tissue engineered lymphatic graft should mimic the mechanical properties of native 
collecting lymphatic vessel. Features of an ideal tissue engineered lymphatic graft are high 
strength and flexibility, good hydraulic conductivity, kink resistant and good suture retention. 
This will ensure that the conduit and anastomosis remains intact especially in regions with 
great range of motion such as the axilla and groin. In terms of achieving a reliable standard 
and to ensure patient’s safety, the International Standard for cardiovascular implant – tubular 
vascular prostheses BS ISO 7198:1998 is an excellent guideline to adhere to at the moment. 
3.3 lymphatic Valve  
The main challenge in the design of artificial lymphatic graft is the inclusion of valves. 
Lymphatic valves are bileaflet and made up of connective tissue lined by LECs which are 
anchored to the base by elastin and collagen that are responsible to resist inversion (26). 
Valves are present at intervals of every few millimetres and usually found in vessel 
bifurcations and branch points (27, 28). Valves function to prevent backflow and is the 
anatomical site of fluid shear sensation for production of nitric oxide to regulate lymphatic 
contractions (29). Valvular dysfunction would exacerbate lymphedema which is witnessed in 
genetic conditions involving lymphatic valve malformation such as in FOXC2 mutation (30). 
Valves also play an important role in sectioning the conduit into shorter segments in order to 
assist capillary action.  
Capillary action is described as (31): 
h = 2γ cosθ 
                   pgr                 (a) 
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Where h is the height of the meniscus, θ is the contact angle, γ is the liquid-air surface tension 
(force/unit length), g is the gravitational acceleration (length/square of time), p is the density 
of liquid (mass/volume), and r is the radius of conduit (length).  
Equation (a) implies that height of capillary action is inversely proportional to the radius of 
the conduit. A simplified assumption using properties of water suggests that the height of 
capillary action is 3.6cm if the r is 0.4mm. However, knowing that the density of lymph is 
greater than that of water, the height of meniscus is expected to be much lower and hence 
capillary action alone is insufficient to drive the lymph through the whole length of lymphatic 
vessels if valves were not present to segment the columns.  
 
3.3 Scaffold 
Tissue engineering is aimed at creating a construct which allows harmonious interaction 
between scaffold, cells and appropriate growth factors (32). An ideal scaffold should bridge 
the gap between lymphatic vessels and guide regeneration of functional lymphatic tissue. The 
importance of designing a conduit with intraluminal valves exclude the possibility of using 
non-scaffold based tissue engineering approach such as ‘sheet-based’ method (22). Scaffold 
for lymphatic graft can be broadly divided into synthetic and natural (decellularized).  
 
3.3.1 Biodegradable synthetic scaffold 
Synthetic scaffold has the advantage of being custom designed and shaped with well-defined 
physical and biochemical property at production. Biodegradable synthetic scaffold acts as 
temporary scaffold prior to being substituted by cellular matrix that is balanced by the 
polymer degradation rate. Polyglycolic acid (PGA) scaffold was used by Dai and colleagues 
to engineer lymphatic vessel and reported successful endothelialization by LEC (33). PGA 
was used due to its well documented biocompatibility as well as the ease in manipulating and 
design. This is the sole reported work on biodegradable lymphatic conduit and despite being 
a preliminary work; it showed the ability of LEC to attach onto polymer scaffold.  
 
3.3.2 Non-biodegradable synthetic scaffold 
This scaffold has stable mechanical strength and able to maintain its shape. The main issue 
with most of these materials used in vascular grafts are maintaining patency of the graft and 
high infection rate especially when the diameter is <5mm (34, 35). This is due to the absence 
of adaptive tissue that is responsive to local environment (36). These limitations have driven 
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researches to develop vascular graft with endothelial cell lining as well as hybrid graft which 
has the combination of mechanical strength and biological cues (37, 38).  
A particular nanocomposite polymer, the UCL-NanoTM (POSS-PCU) is a novel 
nanocomposite developed in our laboratory and has great potential in lymphatic graft 
engineering (39). This polymer has shown several superior properties over present synthetic 
polymer contributed by its surface nanotopography as well as its viscoelastic properties 
(Figure 3). It has been successful in cardiovascular applications such as heart valves and 
bypass graft due to its ideal mechanical and biochemical properties which include 
biocompatibility, durability, ability for biofunctionalization and endothelialization as well as 
anti-thrombogenic property (40-42). These merits are expected to be favourable in the 
engineering of lymphatic graft. This nanomaterial have been used in the development of 
synthetic trachea, lacrimal drainage conduit and vascular bypass graft (43). POSS-PCU has 
also been incorporated with a second polymer polycaprolactone (UCL Nano-BioTM) to 
produce a degradable nanocomposite polymer (44).  
The superior qualities of nanocomposites are contributed by the interaction at nano-scale 
level resulting in the unique quantal properties instead of bulk properties of conventional 
material (45). The general advantages offered by nanocomposites are high surface area to 
mass ratio, thermodynamic stability, bio-stability, amphiphilicity and enhanced mechanical 
property compared to conventional materials for graft. These properties can be enhanced by 
nanofibers and nanotubes as fillers (22). Carbon nanotubes are able to reduce macrophage 
adhesion and proliferation which could prevent blockage of lymph flow (46). However, the 
potential toxicity of carbon nanotube limits its translation potential (47). 
 
3.3.3 Decellularized scaffold 
Decellularized scaffold has been widely used in tissue engineered vascular graft as it 
overcomes the challenge of design and fabrication (48, 49). The pre-formed scaffold caries 
the ECM architecture of native vessel and biochemical cues to support cell viability while 
preserving the bulk mechanical feature of native tissue (50). Wong et al. showed that 
decellularized scaffold can provide necessary extracellular signalling molecules for lymphatic 
tissue regeneration by evaluating lymphatic vessel ingrowth in acellular dermal matrices (51). 
However, decellularized collecting lymphatic vessel has not been used to engineer lymphatic 
graft thus far. In view of the successful clinical application of autologous lymphatic graft by 
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Baumeister, the application of decellularized collecting lymphatic as scaffold should be 
tested. One of the challenges with decellularized scaffold is the extreme density of the matrix 
which delays cell infiltration upon seeding resulting in excess culture time (52). In terms of 
translational potential, decellularized scaffold are often more expensive, limited in resource 
and difficult for surgical manipulation. 
 
 
 
3.4 Endothelialization of lymphatic graft 
Lymphatic endothelium is essential in modulating the fluid flow and dendritic cell transport 
function (53). As compared to vascular graft, lymphatic graft does not hold risk of thrombosis 
however in view of the low flow rate and the content of lymphatic fluid, risk of coagulation 
in the lymphatic graft may be present. The main concern in producing an endothelialised 
construct is the attachment of seeded cells onto scaffold material (33). 
In order to ensure a higher rate of endothelialization and to increase its potential, scaffolds 
could be bio-functionalised with appropriate ligands. Peptide arginine-glycine-aspartic acid 
(RGD) which is the minimal binding domain of fibronectin has been studied 
comprehensively to increase cell adhesion on vascular grafts (42). Peptide RGD forms 
receptor-ligand interactions with integrins on BEC. In order to identify the best form of RGD 
for integrins on LEC, polymer scaffold could be modified with different forms of RGD. This 
bio-functionalised scaffold would provide environment which mimics ECM to help anchor 
LECs to the polymer scaffold.  
Surface topography that is favourable for LEC has yet to be outlined but this feature has been 
extensively explored with regards to vascular graft engineering. Nanostructuralisation 
increases total surface area which in return facilitates protein interaction and promotes cell 
adhesion (54).  
 
3.5 Interstitial flow 
Swartz and colleagues have made great contribution in characterising the importance of 
interstitial fluid flow in regulation of LEC proliferation, function and migration (55). They 
found that BEC and LEC have differential responses to interstitial flow leading to variation in 
cellular morphology and branching patterns indicating that LEC differentiation is influenced 
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by specialised responses from environmental stimuli (56). Similar concept was demonstrated 
in a mouse model showing that interstitial fluid flow guides LEC organisation along the 
direction of flow (57, 58). These suggest that scaffold which encourages interstitial flow is 
vital in engineering lymphatic graft.  
 
3.6 Growth factor 
Regenerative medicine research is likely to produce more effective and better tolerated 
treatment for lymphedema in the long term and proper understanding of lymphangiogenesis 
is the essence of it. Lymphangiogenesis occurs physiologically during wound healing as well 
as pathologically in inflammation, tumours metastasis and transplant rejection (59, 60).  
Table 2 and 3 provides a comprehensive summary of the main molecular factors found to be 
important in normal lymphatic development, function and maintenance. 
In pathological condition such as lymphedema, the vascular endothelial growth factor-C 
(VEGF-C) expression or even over-expression is insufficient to promote lymphatic 
regeneration (61, 62). In such cases, lymphatic function and regeneration could be improved 
by inhibition of transforming growth factor beta-1 (TGF- β1) (63). The TGF- β1 has potent 
anti-lymphangiogenic activity leading to decreased LEC proliferation and in vivo LEC 
migration, impaired lymphatic tubule formation and down regulation of lymphatic specific 
gene expression (63). Furthermore, the uses of anti-lymphangiogenic factors are also 
clinically relevant in cases where VEGF-C is contraindicated such as in immediate post 
cancer resection since VEGF-C expression could contribute to tumour growth and metastasis 
(64). Hence tissue engineering approach could augment lymphangiogenesis by regulating the 
equilibrium between lymphangiogenic and anti-lymphangiogenic forces.  
 
3.7 Gene therapy 
Genetic and recombinant protein therapeutic strategies are likely to enhance 
lymphangiogenesis and treat both primary and secondary lymphedema. Hepatocyte growth 
factor (HGF) gene therapy has successfully stimulated the growth of lymphatic vascular 
system in mouse model (65). HGF plasmid DNA was used in vascular system, heart and lung 
and also reported to be safe in patients with critical limb ischaemia (66, 67). Besides that, 
VEGF-C activation using viral vectors also reported to have potential in lymphedema 
treatment (68). However, VEGF-C therapy was reported to exacerbate oedema by causing 
REVISED 
REVISION DATE: 09/07/2014 
poor functioning and hyperplastic lymphatic vessels(62). Nevertheless, gene therapy and 
growth factors have the potential to be an adjunct to engineered biomaterials which can be 
administered locally or systemically to enhance collateral lymphatic vessel formation and 
also to provide greater biocompatibility for the biomaterial.  
 
 
 
3.8 Cell source 
Common source of LEC isolation is the skin dermis and its isolation from human dermis has 
been well established (69-71). An alternative source of LEC is from pluripotent stem cells 
such as embryonic stem cells that have been reported to differentiate into LECs in vitro in the 
presence of VEGF-C and Ang1 (72). Besides that, mesenchymal stem cells (MSCs) derived 
from bone marrow or adipose tissue also show good potential to differentiate into LECs in 
the company of recombinant VEGF-C (73). Adipose-derived MSCs have been reported to 
improve lymphatic regeneration and restore function upon direct injection into rat hind limb 
and mouse tail models (74). The huge potential of adipose derived stem cells in the field of 
lymphedema should be acknowledged and explored further in view of its abundant resource 
and easy availability (32).   
 
3.9 Animal model 
The first step in developing an animal model to evaluate the effectiveness of the tissue 
engineered lymphatic graft is producing a sustainable model of secondary lymphedema. The 
animal model should permit quantification of lymphatic function over time and allow 
assessment of practical effectiveness of the tissue engineered lymphatic graft. Animal models 
that have been used include dog hind limb models, rabbit ear models and rodent tail and hind 
limb models (75-78). The main limitation of these models are difficulty in quantifying the 
lymphatic function, size that is much smaller than that of human and unsustainable effect of 
lymphedema. Upon lymph node resection, some degree of lymphangiogenesis may take place 
however transport properties exhibited by the newly formed lymphatics are insufficient to 
restore flow parameters to its original state(79). Combination of radiotherapy with surgical 
ablation has shown to induce sustained lympheodema after surgery (80).  
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Tobbia et al outlined the advantage of using sheep as lymphedema model due to the 
anatomical dimension of the lymphatic vessel which allows quantification of lymphatic 
function and therapeutic outcome (81). In their study, the popliteal lymph node was excised 
due to the ease in identification and sufficient size for cannulation. Furthermore, there is just 
one post-nodal duct despite having about 6-12 pre-nodal ducts which is ideal for the 
application of the tissue engineered lymphatic graft. Multiple pre-nodal ducts can be 
anastomosed to the lymphatic graft distally as performed by Campisi with the use of venous 
graft (4). Objective quantification of lymphatic function before and after administration of the 
tissue engineered lymphatic graft can be performed with the usage of radiolabelled human 
serum albumin (81).  
A robust pre-clinical study design is crucial in determining the right time to administer the 
tissue engineered lymphatic graft. Comparison should be made on the benefit of early 
application of the lymphatic graft upon surgical resection of lymph nodes over application 
upon onset of clinical symptoms. Such robust study carries a huge potential to revolutionise 
the current clinical practise in the management of secondary lymphedema.  
 
4.0 CONCLUSION AND FUTURE PROSPECTIVE 
 
Treatment of lymphedema is evolving positively of late due to the growing knowledge in 
lymphatic biology which has enhanced our understanding on lymphatic growth and repair. In 
conjunction with this, more studies need to be carried out to further characterise the human 
lymphatic system in order to bridge the current limitations that exit alongside the promise that 
new technological advancement holds. Tissue engineered lymphatic graft is a tool that could 
benefit many around the world by reducing the morbidity related to lymphedema. 
Furthermore, tissue engineered lymphatic tissue model would be valuable for lymphatic 
biology and cancer research. This could reduce the usage of animal models for lymphatic and 
cancer research. With the in depth understanding of tissue engineering, nanotechnology and 
improved knowledge on biology of lymphatic regeneration, the aspiration to develop 
successful lymphatic graft is highly achievable. A successful lymphatic graft requires design 
which is functional as well as scaffold which encourages and maintains endothelialization 
and mechanical strength. The next step upon creation of successful lymphatic graft is 
regenerating lymphatic network in order to channel lymphatic fluid from the distal part of the 
body to functional host lymphatic vessels. 
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6.0 APPENDIX 
 
6.1 TABLES 
 
Table 1. Characteristics of lymphatic vessels and blood vessels 
 
Table 2. List of molecular factors important in lymphatic system function described 
according to the embryological developmental stage in which discovered.  
 
Table 3. Other factors important in lymphatic function not clearly related to 
embryological development. 
 
6.2 ILLUSTRATIONS 
 
Figure 1. Organisation of lymphatic system 
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Figure 2. Illustration of tissue engineered lymphatic graft bridging damaged lymphatic 
vessel. 
 
Figure 3. SEM image of porous POSS-PCU polymer scaffold extruded with sodium 
bicarbonate (100 µm particle size) porogen. Images are of a longitudinal section.  Note 
the highly porous structure similar to structure of extra cellular matrix indicative of 
possible better tissue engineering properties (highlighted by the arrow); 10 x 
magnification (left), 80x magnification (right). 
 
 
Table 1. 
Characteristic Lymphatic capillary Lymphatic collector Blood vessel 
Diameter 10-60um 50-400um Wide range  
Inner lining 
(intima) 
LEC LEC BEC 
Basement 
membrane 
Patchy or absent. 
Lacks pericytes. 
Continuous, multi-
layered with 
pericytes 
Continuous, multi-
layered with 
pericytes 
Smooth muscle wall 
(media) 
None Present Present 
Valves Primary valve Secondary valve Present in vein 
Subunit None Lymphangion None 
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Table 2.  
(Key:*gene loss lethal, ^gene mutation related to known cases of human primary 
lymphedema) 
Developmental 
step 
Molecular factor Function References 
Competence LYVE-1 
(Lymphatic vessel 
hyaluronan 
receptor-1) 
The first proteins expressed by 
endothelial cells that differentiate into 
LEC. Likely function is to aid leukocyte 
migration via hyaluronan receptor. Is a 
useful LEC marker. 
(82) 
Bias and 
Specification 
Prox-1* 
(homeobox 
transcription 
factor) 
Master control gene, required to 
maintain LEC phenotype. Expression 
can induce LEC like phenotype in 
mature blood endothelial cells.  
(83) 
SOX-18*^ (sex 
determining 
region Y box 18) 
A nuclear transcription factor binds to a 
proximal promoter of the Prox-1 gene. 
Not required for sustaining LEC 
phenotype.  
(84) 
COUP-
TFII*(Chicken 
ovalbumin 
upstream 
promoter 
transcription 
An orphan nuclear receptor that has a 
vital role in organogenesis generally. 
Acts as a regulator of transcriptional 
activity of Prox-1, notably by down 
regulating VEGFR-3 (effects cell 
migration) and cyclin E1 (cell 
(85) 
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factor II) proliferation gene) transcription.  
VEGFR-
3*^(vascular 
endothelial 
growth factor 
receptor 3) 
Vascular endothelial growth factor 
receptor essential for lymphatic as well 
as blood vessel embryological 
development. Becomes specifically 
expressed on LEC’s by birth. Not 
required for LEC phenotype 
maintenance, but is required or 
lymphangiogenesis. Useful LEC marker 
in adults.  
(86, 87) 
VEGF-C* and D Vascular endothelial growth factors - 
ligands for VEGFR-3. The major 
lymphoangiogenic factor. VEGF-D is 
redundant, but can rescue VEGF-C 
deficiency. Not required to maintain 
LEC phenotype, but is required for 
lymphangiogenesis. Both also bind to 
VEGFR-2 present on blood and 
lymphatic vessels. Therapeutic use in 
lymphedema and cancer under 
investigation. 
(88, 89) 
NRP-
2(Neuropilin 2) 
A glycoprotein trans-membrane protein 
binds to VEGFR-2 and 3 and has a 
modulating effect important for normal 
lymphatic development. 
(90) 
Maturation 
 
Syk& SLP-76* 
(tyrosine kinase 
and adaptor 
protein) 
Haemopoeitic signalling proteins 
essential in maintaining blood and 
lymphatic systems separation, 
preventing haemorrhage and organ 
failure.  
(91, 92) 
Spred -1 /2*,  
fasting-induced 
adipose factor 
Spred-1 and 2 are negative regulators 
for growth factors including the VEGF-
C/VEGFR-3 signalling cascade. Have 
(93) 
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(Fiaf), or 
angiopoietin-like 
protein 4 
(Angptl4) 
similar role to Syk or SLp-76. 
Phospholipase 
Cγ2 (PLCγ2). 
PLCy2 like Syk/SLP-76 and Spreds has 
a role in the separation of the lymphatic 
from blood system. 
(94) 
Foxc2^ 
(previously 
known as 
mesenchyme 
forkhead 1 
(MFH1) 
A transcription factor expressed in 
mesenchymal tissue including the heart 
and endothelial cells. Foxc2 deficiency 
leads to severe modelling defects 
resulting in abnormal lymphatic vessels 
lacking valves.  
(95) 
NAFTc1 (Nuclear 
factor of activated 
T cells 1) 
A transcription factor that interacts with 
Foxc2 in remodelling the lymphatic 
vasculature, in particular maturation of 
collecting vessels. 
(96) 
Integrins (α9)* Integrin α9β1 is involved in LEC 
migration towards VEGF-C. Has a 
crucial role in organising fibronectin 
matrix for normal valve development. 
(97) 
Ang2/Tie2 
(Angiopoeitin 
growth factor 
binds to Tie 
receptors) 
Essential in recruiting smooth muscle 
cells to collecting lymphatic vessels and 
patterning of the lymphatic capillaries. 
Ang1 can rescue loss of Ang2, Tie 1 
may have a modulatory role. 
(98) 
EphrinB2 Ephrin B2 acts through Eph B4 receptor 
to regulate maturing lymphatic vessels. 
Mutation of the Ephrin B2 PDZ 
interaction site causes failure of 
hierarchal organisation, failure of valve 
formation and abnormal smooth muscle 
recruitment on lymphatic capillaries.   
(99) 
REVISED 
REVISION DATE: 09/07/2014 
Podoplanin T1α A Mucin-type transmembrane 
glycoprotein. Probable function in cell 
adhesion, migration and tube formation. 
Deficiency results in lymphedema 
secondary to abnormal patterning. 
(100) 
Adrenomedullin* 
(AM) 
Multifunction peptide hormone acts via 
its receptor calcitonin receptor-like 
receptor (calcrl,) and receptor activity-
modifying protein (RAMP2). It is a 
potent inducer of endothelial cell 
proliferation, migration and tube 
formation essential in blood and 
lymphatic development. Under 
investigation for treatment of 
lymphedema. 
(101, 102) 
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Table 3. 
(^gene mutation related to known cases of human primary lymphedema) 
Molecular factor Function References 
Emilin-1 (elastic extra-
cellular matrix microfibril 
associated glycoprotein) 
patterning in relation to anchoring filament 
attachment to the ECM 
(103) 
Ccbe1^ (Collagen and 
calcium-binding EGF 
domain-1) 
Essential in lymphatic development in a zebra 
fish, recent link to human primary lymphedema. 
Has not been found to be expressed in lymphatic 
endothelium and is more likely to be found 
within the ECM. 
(104) 
HGF (hepatocyte growth 
factor) 
Lymphangiogenic growth factor, investigated for 
treatment of lymphedema. 
(105) 
FGF-2 (fibroblast growth 
factor-2) 
Lymphangiogenic growth factor (106) 
PDGF-BB (platelet 
derived growth factor-BB) 
Lymphangiogenic growth factor (106) 
IGF-1/2 (insulin-like 
growth factors) 
Lymphangiogenic growth factor (106) 
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Figure 1.  
 
 
SMC: Smooth muscle cell 
LEC: Lymphatic endothelial cell 
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Figure 2. 
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Figure 3.  
 
 
